Breaking News Instant updates and real-time market news.

TODAY'S FREE FLY STORIES

Hot Stocks
Vulcan Materials sees FY20 aggregates shipments growth of 2%-4% » 07:36
02/18/20
02/18
07:36
02/18/20
07:36
VMC

Vulcan Materials

$146.88 /

+2 (+1.38%)

Sees FY20: Aggregates…

Sees FY20: Aggregates freight-adjusted price increase of 4%-6%; 10%-15% growth in Asphalt, Concrete and Calcium gross profit, collectively; An effective tax rate of approximately 20%.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Plus Products launches PLUS CBDRelief brand into California adult-use market » 07:36
02/18/20
02/18
07:36
02/18/20
07:36
PLPRF

Plus Products

$0.00 /

+ (+0.00%)

Plus Products announced…

Plus Products announced the launch of its new PLUS CBDRelief brand into the California Adult-Use Market. The two new products include a PLUS CBDRelief 9:1 Tropical Mango with 9mg of CBD and 1mg of THC per serving, and a PLUS CBDRelief 18:1 Tart Cherry with 18 mg of CBD and 1 mg of THC per serving. Specifically formulated to help reduce chronic subclinical inflammation, provide full-body relief and promote a calm state of mind, the proprietary blends mix CBD and THC to provide powerful relief. PLUS CBDRelief products are expected to be sold in licensed retailers across California.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Alibaba price target raised to $250 from $212 at SunTrust » 07:36
02/18/20
02/18
07:36
02/18/20
07:36
BABA

Alibaba

$219.60 /

-0.735 (-0.33%)

SunTrust analyst Youssef…

SunTrust analyst Youssef Squali raised his price target on Alibaba to $250 and kept his Buy rating after its December quarter earnings exceeded expectations on "virtually every metric". The analyst believes that the management has continued its "solid execution" against a "massive" growth opportunity, with the company gaining market shares in e-commerce both inside and outside of China. Squali adds that while coronavirus adds "material uncertainty" for Alibaba in the near term, it may also accelerate the "online" shift in consumption, particularly in lower-tier cities.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays » 07:36
02/18/20
02/18
07:36
02/18/20
07:36
SGEN

Seattle Genetics

$118.09 /

-0.16 (-0.14%)

Barclays analyst Gena…

Barclays analyst Gena Wang downgraded Seattle Genetics to Equal Weight from Overweight with an unchanged price target of $124. The analyst continues to like Seattle Genetics' ADC technology platform and remains optimistic about the commercial opportunities for Padcev and tucatinib. However, she sees a balanced risk/reward profile at current share levels.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Axon announces over a thousand Axon Body 3 cameras are deployed in Cincinnati » 07:35
02/18/20
02/18
07:35
02/18/20
07:35
AAXN

Axon

$87.00 /

-0.71 (-0.81%)

Axon announced that more…

Axon announced that more than 1,000 Axon Body 3 cameras are now deployed in Cincinnati as part of a previously announced order of the Officer Safety Plan 7+. The plan includes several products on the Axon network including TASER 7, Axon Body 3, unlimited Axon Evidence, the new advanced AI-powered tool, Redaction Assistant, and the public evidence submission tool, Axon Citizen for Communities. Axon Body 3 began shipping in September 2019 and features LTE connectivity, live video streaming features, and GPS.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Unusual call flow in option market yesterday » 07:35
02/18/20
02/18
07:35
02/18/20
07:35
UBER

Uber

$39.63 /

-0.46 (-1.15%)

Notable call activity was…

Notable call activity was cited Friday in Uber (UBER).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
FX Update: The yen and Swiss franc firmed » 07:35
02/18/20
02/18
07:35
02/18/20
07:35

FX Update: The yen and…

FX Update: The yen and Swiss franc firmed as risk-off positioning took a grip after Apple warned that it would missed Q1 revenue guidance, pointing to a slow rebound in factory output in China and forcing a rethinking on the likely impact that the measures being taken to stem contagion of the coronavirus have been having. Regional currencies in Asia have taken a hit, as have the dollar bloc currencies, while dollar has traded mixed. USD-JPY retreated to a five-day low at 109.65, while AUD-JPY posted an eight-day low at 73.28. USD-CAD lifted above Monday's high in making 1.3255, with the Canadian dollar weakening concomitantly with a 1%-plus drop in oil prices. Elsewhere, EUR-USD eked out a fresh 34-month high at 1.0820, even though the pair has only seen a 18-pip range so far today. Cable rebounded to a high of 1.3048 after posting a five-day low at 1.2980. News that that the government's 2020-21 budget presentation won't be delayed (as had been speculated), and data showing a new record high in employment in the UK, gave sterling a boost.

Hot Stocks
Franklin Templeton to acquire Legg Mason for $50.00 per share  07:34
02/18/20
02/18
07:34
02/18/20
07:34
BEN

Franklin Resources

$24.37 /

+0.155 (+0.64%)

, LM

Legg Mason

$40.72 /

-0.02 (-0.05%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays » 07:34
02/18/20
02/18
07:34
02/18/20
07:34
KOD

Kodiak Sciences

$59.96 /

-2.77 (-4.42%)

Barclays analyst Gena…

Barclays analyst Gena Wang downgraded Kodiak Sciences to Equal Weight from Overweight with a price target of $69, up from $26. After the recent Angiogenesis update, the analyst does not see major upside from Phase 1b long-term data. As such, she sees a balanced risk/reward for the shares before Phase 3 trials read out starting on the second half of 2022. Her increased price target reflects enhanced conviction on KSI-301's clinical profile and market opportunity.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Vulcan Materials sees FY20 adjusted EBITDA $1.385B-$1.485B » 07:34
02/18/20
02/18
07:34
02/18/20
07:34
VMC

Vulcan Materials

$146.88 /

+2 (+1.38%)

Tom Hill, Chairman and…

Tom Hill, Chairman and CEO, said, "2019 marks another year of strong earnings growth and cash generation. We are particularly proud of our people who worked hard to achieve these results while ensuring another year of world-class safety performance. Widespread improvements in pricing helped drive 8 percent growth in our industry-leading unit profitability and double-digit growth in Adjusted EBITDA, a strong result despite some higher than expected costs in the fourth quarter. Industry leadership in safety and pace-setting unit margins are both evidence of our strong and healthy business. Going forward, our compounding unit margins and our disciplined capital allocation position us to increase our cash flows and improve our return on invested capital again in 2020. Looking ahead, demand in our markets will continue to benefit from higher levels of highway funding and continued growth in residential and nonresidential markets. This visibility into demand growth has already set the stage for solid price improvement in 2020. Price improvement coupled with our four strategic initiatives (Commercial and Operational Excellence, Logistics Innovation and Strategic Sourcing) should continue to increase unit profitability. For the full year, we expect earnings from continuing operations between $5.20 and $5.80 per diluted share with Adjusted EBITDA between $1.385 and $1.485 billion."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Pixelworks, Qualcomm collaborate to integrate live local TV with 5G broadband » 07:33
02/18/20
02/18
07:33
02/18/20
07:33
PXLW

Pixelworks

$4.85 /

+0.28 (+6.13%)

, QCOM

Qualcomm

$89.59 /

-0.43 (-0.48%)

Pixelworks (PXLW)…

Pixelworks (PXLW) announced the Company is working with Qualcomm Technologies (QCOM) on a 5G-based fixed wireless access customer-premises equipment platform that integrates over-the-air local TV streaming technology from Pixelworks. The joint reference solution will combine Pixelworks' OTA streaming XCode processor with the Qualcomm Snapdragon X55 5G Modem-RF System, allowing broadband network operators, Internet Service Providers and original equipment manufacturers to rapidly develop and deploy a comprehensive home video solution.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Moleculin Biotech announces data from its CTCL clinical trial of WP1220 » 07:33
02/18/20
02/18
07:33
02/18/20
07:33
MBRX

Moleculin Biotech

$0.75 /

+0.024 (+3.31%)

Moleculin Biotech…

Moleculin Biotech announced the final data from its CTCL clinical trial of WP1220 for the treatment of cutaneous T-cell lymphoma, or CTCL, which was published and presented by Dr. M. Sokolowska-Wojdylo in conjunction with the 4th Annual World Congress of Cutaneous Lymphomas in Barcelona, Spain on February 13. The final results supported the safety of topical WP1220 and demonstrated a median improvement in the Composite Assessment of Index Lesion Severity, or CAILS,score of 56% in treated lesions for patients completing the study. Mycosis Fungoides or MF, the most common variant of CTCL, is a disease with symptomatic, disfiguring skin lesions. Of 5 subjects enrolled, 9 lesions were assessed according to the CAILS scoring system. The only adverse event was mild contact dermatitis in one subject felt not to be related to the drug. 4 of the 5 subjects had significant improvement in CAILS scores on index lesions, with a median reduction of 56%. Improvement was noted within 7 days of treatment initiation and maintained 1 month after discontinuation. Independent dermatologic review based on photographic documentation was conducted and corroborated these findings. WP1220, an inhibitor of p-STAT3, shows safety and significant efficacy in MF after topical treatment. We believe this is the first demonstration in humans that inhibition of p-STAT3 with topical therapy has efficacy in CTCL. A larger Phase 2 study is now being planned.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Alliance Data reports January net charge offs 7.2% vs. 6.1% last month » 07:32
02/18/20
02/18
07:32
02/18/20
07:32
ADS

Alliance Data

$102.81 /

-0.64 (-0.62%)

Reports January…

Reports January delinquency ratio 6.0% vs. 5.8% last month.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Eidos Therapeutics downgraded to Underweight from Equal Weight at Barclays » 07:32
02/18/20
02/18
07:32
02/18/20
07:32
EIDX

Eidos Therapeutics

$52.09 /

-1.635 (-3.04%)

Barclays analyst Gena…

Barclays analyst Gena Wang downgraded Eidos Therapeutics (EIDX) to Underweight from Equal Weight with an unchanged price target of $45. While the analyst believes AG-10 could be as good as Pfizer's (PFE) tafamidis and that the ATTRibute-CM Phase 3 study in ATTR-CM will likely be positive, she believes tafamidis launch trajectory has so far been largely in line with expectation and Eidos shares fully reflect the market opportunity. As such, and given a lack of other major catalysts, Wang believes other companies could provide more upside potential.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Caleres price target lowered to $20 from $27 at Wedbush » 07:31
02/18/20
02/18
07:31
02/18/20
07:31
CAL

Caleres

$14.31 /

-3.58 (-20.01%)

Wedbush analyst…

Wedbush analyst Christopher Svezia lowered his price target for Caleres to $20 from $27 after the company pre-announced Q4 sales about $50M below consensus driven by weakness in the higher margin Brand Portfolio, slightly offset by the strongest comp at Famous Footwear since 2013. The analyst has an Outperform rating on the shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Vulcan Materials sees FY20 cont ops EPS $5.20-$5.80, consensus $5.72  07:31
02/18/20
02/18
07:31
02/18/20
07:31
VMC

Vulcan Materials

$146.88 /

+2 (+1.38%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Tesla valuation remains "on Mars", says Cowen » 07:31
02/18/20
02/18
07:31
02/18/20
07:31
TSLA

Tesla

$799.95 /

-4.05 (-0.50%)

Cowen analyst Jeffrey…

Cowen analyst Jeffrey Osborne views Tesla positively by taking advantage of the staggering dislocation between its stock price and their assessment of its fair value to raise additional capital. The analyst said he sees a lot of execution risk in the growth story and after updating his model for the capital raise said its valuation "remains on Mars". Osborne maintains his Underperform rating and raised his price target to $290 from $280 on Tesla shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Synopsys initiated with an Overweight at Atlantic Equities » 07:31
02/18/20
02/18
07:31
02/18/20
07:31
SNPS

Synopsys

$163.38 /

+2.04 (+1.26%)

Atlantic Equities analyst…

Atlantic Equities analyst Ianjit Bhatti initiated coverage of Synopsys with an Overweight rating and $200 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Vulcan Materials reports Q4 adjusted EPS $1.08, consensus $1.17 » 07:30
02/18/20
02/18
07:30
02/18/20
07:30
VMC

Vulcan Materials

$146.88 /

+2 (+1.38%)

Reports Q4 revenue…

Reports Q4 revenue $1.19B, consensus $1.19B.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Centerra Gold reports fatality at Kumtor Mine » 07:30
02/18/20
02/18
07:30
02/18/20
07:30
CAGDF

Centerra Gold

$0.00 /

+ (+0.00%)

Centerra Gold announces…

Centerra Gold announces that on February 15, 2020, a fatality occurred at the Kumtor Mine located in the Kyrgyz Republic. A Kumtor employee succumbed to a fatal injury while operating an excavator, which tipped and then slipped down into a water-filled basin near the edge of Petrov Lake, which is situated approximately five kilometres northeast of the Kumtor mill site. An internal investigation has commenced and Kumtor management is working closely with the Kyrgyz regulators and other state authorities to ascertain the cause of the incident.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Unusual put flow in option market yesterday » 07:30
02/18/20
02/18
07:30
02/18/20
07:30
X

U.S. Steel

$8.80 /

-0.16 (-1.79%)

, GLW

Corning

$28.59 /

-0.13 (-0.45%)

Notable put activity was…

Notable put activity was cited Friday in US Steel (X) and Corning (GLW).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Morgan Stanley a buyer of Palo Alto Networks shares ahead of results » 07:29
02/18/20
02/18
07:29
02/18/20
07:29
PANW

Palo Alto Networks

$247.15 /

+1.625 (+0.66%)

Morgan Stanley analyst…

Morgan Stanley analyst Keith Weiss said he would be a buyer of Palo Alto Networks shares ahead of the company's Q2 report as his checks point to continued strong traction with Next-Gen Cloud offerings and stability in the firewall business. The weaker firewall results seen in Q1 were due to execution issues around balancing salesforce priorities, not a fundamental flaw in the company's strategy or a sign of a change in competitiveness in their core markets, contends Weiss, who has an Overweight rating and $315 price target on Palo Alto shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
United Fire Group reports Q4 adj. EPS ($1.04), two est. (64c) » 07:28
02/18/20
02/18
07:28
02/18/20
07:28
UFCS

United Fire Group

$44.79 /

-1.75 (-3.76%)

Reports book value per…

Reports book value per share $36.40. Our 2019 results were negatively impacted by commercial auto losses and prior year reserve strengthening in our Gulf Coast Region," stated Randy A. Ramlo, President and Chief Executive Officer. "From a profitability standpoint, the fourth quarter was disappointing and an unacceptable end to a year in which we failed to meet expectations and failed to make an operational profit. Commercial auto losses continued to be the main driver of the net operating loss in the fourth quarter. We know we have work to do and are focused on aggressively moving forward with our strategic plan to improve profitability. As part of our strategic plan, we currently have several initiatives underway in underwriting, claims, analytics, portfolio management and technology innovation, to name some of our focus areas. One example of a noteworthy development at UFG is within our portfolio management strategy, specifically related to our commercial auto book. Despite our best efforts to manage poor-performing commercial auto accounts with double-digit rate increases and non-renewals, these efforts proved insufficient to return this line of business to underwriting profitability in 2019. With the continued escalation of commercial auto losses industry-wide and no signs of improvement in the key auto metrics we track, such as miles driven, driver shortages, distracted driving and social inflation, we decided to take several difficult but necessary actions beginning in the fourth quarter. Our plans include to be even more aggressive with non-renewals in 2020 which will reduce our commercial auto unit counts, especially in poor-performing segments, and not write new classes of business that are auto heavy. By taking these actions, we're confident we'll achieve a better balance in our overall book of business, which has become too heavily weighted in commercial auto in recent years. Although we stand to lose some of our commercial package policy business as a consequence of this action, we believe it will have the most immediate and profound impact on our profitability. As we move forward with our strategic plan we will closely monitor key metrics and make adjustments accordingly."

ShowHide Related Items >><<
Recommendations
U.S. Semi companies will need to lower Q1/Q2 guidance, says Credit Suisse » 07:28
02/18/20
02/18
07:28
02/18/20
07:28
AAPL

Apple

$324.91 /

-0.02 (-0.01%)

Credit Suisse analyst…

Credit Suisse analyst John Pitzer notes that Apple negatively pre-announced Q2 without providing an updated range due to negative yet still unquantifiable impact of nCoV on both global supply and domestic China demand - ex China demand is in-line with original expectations. The analyst believes that impacts from nCoV are not limited to Apple, and in fact "one could argue that [Apple]'s largess would perhaps give them priority over others and minimize their impact - it's likely worse for others." Pitzer would also stress that nCoV distributions are unlikely to be unique to tech. He expects that most U.S. Semi companies will need to lower Q1/Q2 guidance albeit lack of near-term clarity suggests negative preannouncements are unlikely until March and perhaps not until the second half of March.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Pros Holdings initiated with an Equal Weight at Morgan Stanley » 07:27
02/18/20
02/18
07:27
02/18/20
07:27
PRO

Pros Holdings

$51.12 /

-0.17 (-0.33%)

Morgan Stanley analyst…

Morgan Stanley analyst Stan Zlotsky initiated coverage of Pros Holdings with an Equal Weight rating and $52 price target. The company provides a "powerful" artificial intelligence-driven price optimization platform pursuing a large $10B total addressable market, Zlotsky tells investors in a research note. Pros' model transition is entering the final stages, which should improve subscription revenue stacking and margins, adds the analyst. However, Zlotsky believes the stock's current valuation "well reflects these transition benefits."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.